Capivasertib

Capivasertib is a targeted small-molecule therapy developed for the treatment of hormonally driven breast cancer with specific genetic alterations. It represents a next-generation approach in precision oncology, focusing on intracellular signaling pathways that play a central role in cancer cell growth, survival, and treatment resistance.

At the molecular level, Capivasertib is a selective inhibitor of AKT (protein kinase B), a key component of the PI3K/AKT signaling pathway. Dysregulation of this pathway—often caused by alterations in genes such as PIK3CA, AKT1, or PTEN—is associated with tumor progression and reduced response to endocrine therapy. By inhibiting AKT, Capivasertib helps restore pathway control and enhances the effectiveness of combination treatment strategies.

Because Capivasertib is used in genetically defined patient populations and in combination regimens, molecular purity, stability, and consistency are critical. These attributes support predictable pharmacological behavior, clinical reliability, and compliance with international regulatory standards.

Prescribing Information

Prescribing information provides official guidance on approved indications, dosing schedules, administration instructions, contraindications, and safety monitoring.

Clinical Trial Details

The clinical efficacy of Capivasertib was established through pivotal studies evaluating its use in combination with endocrine therapy.

The key Phase III trial CAPItello-291 demonstrated significant improvement in progression-free survival in patients with HR-positive, HER2-negative advanced breast cancer, particularly in tumors with PIK3CA, AKT1, or PTEN alterations.

FDA Approval Status

Capivasertib is approved by the U.S. Food and Drug Administration for use in combination with endocrine therapy for adults with HR-positive, HER2-negative advanced or metastatic breast cancer harboring specific pathway alterations. It is marketed under the brand name Truqap® by AstraZeneca.